Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Downstream Revenue Generated by Patients With Hereditary Cancer in the Multigene Panel Testing Era.

JCO oncology practice - 1 Dec 2024

Mauer Hall Caitlin B, Reys Brian D, Gemmell Amber P, Campbell Connor L, Pirzadeh-Miller Sara M

Abstract excerpt

PURPOSE: Patients with hereditary cancer syndromes face increased medical management recommendations to address their cancer risks. As multigene panels are the standard of testing today, more patients needing clinical intervention are being identified. This study calculates the downstream revenue (DSR) generated by patients ascertained by a genetic counselor (GC) with a hereditary cancer likely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Genetic Counseling
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Neoplasms

Share to Neoplastic Syndromes, Hereditary

Source

Identifiers

PMID: 38815190
DOI: 10.1200/OP.23.00817

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Downstream Revenue Generated by Patients With Hereditary Cancer in the Multigene Panel Testing Era.PMID 38815190Read ↗

Downstream Revenue Generated by a Cancer Genetic Counselor.Semantic proximity Read ↗

Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients.Semantic proximity Read ↗

Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study.Semantic proximity Read ↗

The clinical utility and costs of whole-genome sequencing to detect cancer susceptibility variants—a multi-site prospective cohort studySemantic proximity Read ↗

Changes in multi-gene cancer panels for children: A 4-year retrospective review.Semantic proximity Read ↗

Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.Semantic proximity Read ↗

Secondary findings after multi-gene panel testing in 7,388 patients with suspected cancer predisposition syndrome.Semantic proximity Read ↗

Genetic findings and health care utilization among individuals undergoing population genomic screening for actionable hereditary disorders.Semantic proximity Read ↗

Cost-effectiveness of Genetic Testing of Endocrine Tumor Patients Using a Comprehensive Hereditary Cancer Gene Panel.Semantic proximity Read ↗

Hereditary cancer testing challenges: assembling the analytical pieces to solve the patient clinical puzzle.Semantic proximity Read ↗

Risks and Implications of Multiple Actionable Pathogenic Germline Variants Discovered by Panel-Based Cancer Predisposition Testing.Semantic proximity Read ↗

Clinical Integration of Germline Findings from a Tumor Testing Precision Medicine ProgramSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.